IL307794A - Treatment of eye diseases using endothelin receptor antagonists - Google Patents

Treatment of eye diseases using endothelin receptor antagonists

Info

Publication number
IL307794A
IL307794A IL307794A IL30779423A IL307794A IL 307794 A IL307794 A IL 307794A IL 307794 A IL307794 A IL 307794A IL 30779423 A IL30779423 A IL 30779423A IL 307794 A IL307794 A IL 307794A
Authority
IL
Israel
Prior art keywords
treatment
receptor antagonists
endothelin receptor
ocular diseases
ocular
Prior art date
Application number
IL307794A
Other languages
English (en)
Hebrew (he)
Inventor
Cheng-Wen Lin
Angela Dawn Glendenning
Sevgi Gurkan
Original Assignee
Perfuse Therapeutics Inc
Lin Cheng Wen
Angela Dawn Glendenning
Sevgi Gurkan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc, Lin Cheng Wen, Angela Dawn Glendenning, Sevgi Gurkan filed Critical Perfuse Therapeutics Inc
Publication of IL307794A publication Critical patent/IL307794A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL307794A 2021-04-30 2022-04-29 Treatment of eye diseases using endothelin receptor antagonists IL307794A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182750P 2021-04-30 2021-04-30
PCT/US2022/027045 WO2022232586A1 (en) 2021-04-30 2022-04-29 Treatment of ocular diseases using endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
IL307794A true IL307794A (en) 2023-12-01

Family

ID=83848733

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307794A IL307794A (en) 2021-04-30 2022-04-29 Treatment of eye diseases using endothelin receptor antagonists

Country Status (9)

Country Link
US (1) US20240058265A1 (https=)
EP (1) EP4329810A4 (https=)
JP (1) JP2024516829A (https=)
CN (1) CN117295520A (https=)
AU (1) AU2022264438A1 (https=)
CA (1) CA3218398A1 (https=)
IL (1) IL307794A (https=)
MX (1) MX2023012826A (https=)
WO (1) WO2022232586A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
BRPI1013904A2 (pt) * 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20120087864A1 (en) * 2010-04-12 2012-04-12 R-Tech Ueno, Ltd. Method for diagnosing and/or evaluating retinal disease
CA2949954A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン,キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Also Published As

Publication number Publication date
MX2023012826A (es) 2023-11-13
US20240058265A1 (en) 2024-02-22
WO2022232586A1 (en) 2022-11-03
EP4329810A4 (en) 2025-02-26
EP4329810A1 (en) 2024-03-06
CN117295520A (zh) 2023-12-26
CA3218398A1 (en) 2022-11-03
JP2024516829A (ja) 2024-04-17
AU2022264438A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
IL276383B1 (en) Treatment of ophthalmological diseases
IL289405A (en) Personalized treatment of eye diseases
EP4050997A4 (en) TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
IL291665A (en) Inhibitors of receptor interaction with protein kinase i for the treatment of disease
HUE067909T2 (hu) Pirimidin JAK-inhibitorok bõrbetegségek kezelésére
BR112017024852A2 (pt) antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual
IL287802A (en) Preparations and methods for the treatment of eye diseases
IL268357A (en) Photoreceptor cells for the treatment of retinal diseases
EP3271015B8 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
GB201805100D0 (en) Treatment of sarcopenic diseases
PT3603621T (pt) Lipossomas para o tratamento de doenças oculares
IL282361A (en) Treatment for neurological diseases
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
IL307794A (en) Treatment of eye diseases using endothelin receptor antagonists
IL291439A (en) Methods for treating autoimmune diseases using interleukin-17 (il-17) antagonists
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
IL306009A (en) Ocular transfer of therapeutic agents
HK40107454A (en) Treatment of ocular diseases using endothelin receptor antagonists
IL299383A (en) Use of N-phenylacetamides with P2X4 receptor antagonist activity to treat certain eye disorders
HK40080625A (en) Treatment of ocular diseases using endothelin receptor antagonists
IL255796A0 (en) Manual implantation devices for transplanting a retinal tissue graft
IL290079A (en) Use of very strong multimeric antagonists for selectin-e for the treatment of sickle cell anemia